Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc.
Your view on JUNS
Overview
What the company does, where it operates, and who runs it.
About Jupiter Neurosciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Christer Rosen
- Headquarters
- 1001 North US HWY 1, Jupiter, FL, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Christer Rosen
- Headquarters
- 1001 North US HWY 1, Jupiter, FL, US
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation.
It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I.
The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.
In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021.
The company was founded in 2016 and is headquartered in Jupiter, Florida.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Jupiter Neurosciences, Inc., and the rating behind it. JUNS last traded at $3.05; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Jupiter Neurosciences, Inc.. Starting points for Jupiter Neurosciences, Inc.: EPS -$16.50, beta 1.79 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Jupiter Neurosciences, Inc.. Jupiter Neurosciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Jupiter Neurosciences, Inc.. Trailing twelve-month EPS for Jupiter Neurosciences, Inc. stands at -$16.50. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Jupiter Neurosciences, Inc.. Jupiter Neurosciences, Inc. has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Jupiter Neurosciences, Inc. valued side by side against its closest peers. Jupiter Neurosciences, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Jupiter Neurosciences, Inc., and how their positions are changing. At a $1.5M market value, institutional positions materially move Jupiter Neurosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Jupiter Neurosciences, Inc. executives and directors. Shares of Jupiter Neurosciences, Inc. have traded between $0.51 and $19.51 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Jupiter Neurosciences, Inc.. Jupiter Neurosciences, Inc. is a $1.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Jupiter Neurosciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Jupiter Neurosciences, Inc.. Coverage tracks Jupiter Neurosciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.